• About us
• Contact

Advertisement

Organisation › Details

ProQR Therapeutics B.V.

We are an innovative biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis. Utilizing our unique, proprietary RNA repair technologies, we believe we will be able to treat genetic disorders in which a single protein is defective due to certain types of genetic mutation. We believe that this is a unique approach that offers advantages compared with small molecule, gene therapy and other therapeutic strategies. *

 

	Start	2014-08-20 existent
	End	2014-09-23 renamed
	Group	ProQR Therapeutics (Group)
	Today	ProQR Therapeutics N.V. (Nasdaq: PRQR)
	Successor	ProQR Therapeutics N.V. (Nasdaq: PRQR)
	Industry	BIOTECH
	Industry 2	QR-010 (ProQR Therapeutics)
	Person	de Boer, Daniel A. (ProQR Therapeutics 201408 CEO)
	Person 2	Termeer, Henri A. (Genzyme 1985–201106 CEO joined Genzyme 1983)
	Region	Leiden
	Country	Netherlands
	Street	24 Darwinweg
	City	2333 CR Leiden
	Tel	+31-85-489-4932
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for ProQR Therapeutics (Group)

• [1] ProQR Therapeutics N.V.. (10/29/18). "Press Release: ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals". Leiden....
• [2] Breath Therapeutics B.V.. (7/11/18). "Press Release: Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer". Munich, Frankfurt & Boston, MA....
• [3] ProQR Therapeutics N.V.. (11/14/17). "Press Release: ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares". Leiden....
• [4] ProQR Therapeutics N.V.. (11/13/17). "Press Release: ProQR Announces Proposed Public Offering of Ordinary Shares". Leiden....
• [5] ProQR Therapeutics N.V.. (11/13/17). "Press Release: ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness". Leiden....
• [6] ProQR Therapeutics N.V.. (11/9/17). "Press Release: ProQR Appoints Thaddeus Dryja, M.D., to Scientific Advisory Board". Leiden....
• [7] Amylon Therapeutics B.V.. (9/12/17). "Press Release: Amylon Therapeutics Announces Seed Investment Round, Focus on CNS disorders". Leiden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.